维罗非尼新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP43160CAS号：1029872-54-5纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	1029872-54-5	货号	BCP43160
关联产品	918504-65-1（维罗非尼）
中文名	维罗非尼
英文名	Vemurafenib
中文别名
英文别名	PLX4032;PLX-4032;PLX 4032;
SMILES	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
化学名称
分子式	C23H18ClF2N3O3S	分子量	489.92
纯度	98%	配送	惯例下常温包邮
产品描述	Vemurafenib is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.

维罗非尼 新